NADIA FERNANDEZ: Open Payments
NPI 1821438169 · HOLLYWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,514 in 171 payments from 20 companies in 2025. Trend: 2023 $47 · 2024 $1,053 · 2025 $4,514
Food & beverage: $4,514
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $766 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $562 |
| Axsome Therapeutics, Inc. | 15 | $415 |
| Otsuka America Pharmaceutical, Inc. | 17 | $405 |
| Vanda Pharmaceuticals Inc. | 10 | $385 |
| ABBVIE INC. | 18 | $385 |
| E.R. Squibb & Sons, L.L.C. | 8 | $291 |
| Braeburn Inc. | 12 | $241 |
| Bausch Health US, LLC | 8 | $190 |
| Teva Pharmaceuticals USA, Inc. | 14 | $189 |
Products named: INGREZZA, CAPLYTA, REXULTI, Auvelity, VRAYLAR, COBENFY, BRIXADI, HETLIOZ.
Industry payments across FL — which companies pay providers there.
